Italian pharmaceutical company DuLac Farmaceutici is continuing discussions with prospective retail and distribution partners after participating in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, held September 14-17 in Palm Beach Gardens, Florida. The meetings marked another step in the company's effort to build a broader U.S. retail presence beyond its established Amazon business.
The event provided an opportunity for DuLac to discuss its Italian-developed portfolio with buyers across health, specialty, food, drug, and mass retail channels. The company is now following up to explore product assortment and distribution opportunities in the United States. DuLac's portfolio includes its high-concentration Arnica Gel 98% range, topical leg-care products, and the Dinaven and Diosmin lines, reflecting more than 30 years of pharmaceutical industry experience.
DuLac enters these discussions with products already available to U.S. consumers through its Amazon storefront and OneLavi. Customer feedback offers a reference point for prospective partners: the company's Arnica Gel 98% listing on Amazon.com has an average customer rating of 4.5 out of 5 stars.
"Our priority following ECRM is to work with prospective partners to identify the DuLac products that best fit their customers and channels," said Gabriele Bollani, Founder and CEO of DuLac Farmaceutici. "We want to build lasting relationships by combining our Italian formulation and manufacturing expertise with a clear understanding of each partner's commercial needs."
During the meetings, DuLac introduced buyers to the research and manufacturing approach behind its products, including its proprietary Arnica Montana Arricchita™ project and its work with botanical ingredients and advanced extraction technologies. The company's European pharmacy heritage and Italian production provide the foundation for its portfolio. Follow-up discussions will focus on the products relevant to each prospective partner, their positioning, and the requirements for a potential launch.
Following ECRM, DuLac is continuing discussions with prospective partners to assess product assortment, channel fit, and distribution opportunities, while building on its existing U.S. e-commerce presence. The company's long-term objective is to establish DuLac as a nationally recognized U.S. brand across multiple channels, combining its European pharmacy heritage and Italian manufacturing with the consumer traction it has already established in the American market. For more information, visit DuLac Farmaceutici.
This expansion matters because it signals growing competition in the U.S. health and wellness retail sector, where European brands are leveraging pharmaceutical-grade manufacturing to capture consumer interest. For retailers, DuLac's portfolio offers differentiated products with proven online demand. For consumers, broader availability could mean easier access to Italian-made botanical formulations. The move also highlights the increasing importance of e-commerce as a springboard for international brands entering physical retail. As DuLac pursues national recognition, its progress will be watched by industry observers assessing the appeal of European dermo-cosmetics in the U.S. market.
